Fractyl Health to Showcase Innovative Data at Scientific Sessions
Fractyl Health, Inc. (Nasdaq: GUTS), a pioneering company in metabolic therapeutics, has exciting news to share. The company is gearing up to present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the prestigious American Diabetes Association's Scientific Sessions. This event is set to take place in Chicago and promises to be a significant moment for researchers and health professionals in the field of diabetes treatment.
Details of the Poster Presentation
During the Late Breaking Poster Session, Fractyl Health will unveil its research under the session title: Late Breaking Poster Session. The abstract details an innovative approach—Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice. This research is particularly pertinent as it aims to highlight preventative measures against obesity and diabetes, conditions that are prevalent and concerning in today's health landscape.
Key Presentation Information
Those attending the event will find the poster, numbered 1970-LB, presented on Sunday, 12:30 p.m. to 1:30 p.m., in Poster Hall (Hall F1, Level 3). After the presentation, attendees can look for the poster on Fractyl Health's website under the Presentations & Publications section.
Transforming Metabolic Disease Treatment
Fractyl Health emphasizes its mission to change the way metabolic diseases, especially obesity and type 2 diabetes (T2D), are addressed. Traditionally, treatments have focused on managing symptoms rather than targeting their root causes. The innovative Rejuva platform aims to offer patients durable, disease-modifying therapies, addressing the underlying factors contributing to these conditions.
Insights into the Rejuva Platform
The Rejuva platform is designed to utilize next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies. Currently, it remains in preclinical development. Its advanced delivery systems and proprietary screening methods are engineered to identify effective, metabolically active gene therapy candidates that directly target the pancreas. This strategy reflects Fractyl Health's commitment to revolutionizing the understanding and treatment of metabolic diseases.
Ongoing Commitment to Research and Development
As part of its continuous improvement and innovation strategies, Fractyl Health is dedicated to exploring the therapeutic potential of gene therapies. The company understands the urgent need for effective treatments, especially given the rising rates of obesity and T2D. With its location in Burlington, MA, Fractyl Health is strategically positioned to lead efforts in addressing these health issues.
Connect with Fractyl Health
For those interested in following the latest updates, Fractyl Health provides various points of contact. Media representatives can reach out to Jessica Cotrone, Head of Corporate Communications, at jcotrone@fractyl.com or call 978.760.5622. Investors are invited to connect with Brian Luque, Head of Investor Relations, via IR@fractyl.com or by calling 951.206.1200, to discuss their insights and strategies moving forward.
Frequently Asked Questions
What is Fractyl Health focused on?
Fractyl Health is dedicated to developing innovative therapies for metabolic diseases, specifically targeting obesity and type 2 diabetes.
When will Fractyl Health present its new data?
The poster presentation will occur on a Sunday during the American Diabetes Association’s Scientific Sessions.
What is the purpose of the Rejuva platform?
The Rejuva platform aims to create modified gene therapies that directly address and prevent obesity and diabetes through targeted approaches.
How can I access the poster after the presentation?
The poster will be available on the Fractyl Health website in the Presentations & Publications section following the conference.
Who should I contact for more information about Fractyl Health?
Please reach out to Jessica Cotrone for media inquiries or Brian Luque for investor relations for further information.
